Antiviral Innovations Targeting Celiac Disease
Viral Triggers and Genetic Susceptibility
Understanding and Preventing Celiac Disease
Celiac disease arises when genetically predisposed individuals mount an abnormal immune response against dietary gluten. Enteroviruses have associated with increased risk of celiac disease and they have been found in the intestinal mucosa of affected patients, suggesting their potential involvement. Notably, the prevalence of celiac disease is higher among those with type 1 diabetes, reinforcing a potential shared viral trigger.
Vactech’s innovative antiviral approach, supported by patented technology, offers promising possibilities for both preventing the onset and providing treatment options for celiac disease, addressing an important unmet medical need. PRV-101 vaccine includes enterovirus serotypes which have been linked to celiac disease, being the most promising approach for prevention.
“Emerging research suggests that enteroviral infections may act as environmental triggers in the development of celiac disease. At Vactech, we are advancing targeted antiviral strategies and vaccine technologies to address this pathway — with the goal of preventing disease onset and bringing new solutions to individuals at risk.” Mikael Knip - Member of the Board, Cofounder, Professor of Pediatrics, MD, PhD